manufacturing
-
Eli Lilly Plans New $2.5B Manufacturing Site in Germany for Injectable Meds
The German manufacturing site is the latest capital infrastructure move for Eli Lilly, which has already made $11 billion in investments in its global manufacturing capabilities in the past three years. The new site will help Lilly meet strong demand for its diabetes and obesity drugs.
-
Ajinomoto Adds Gene Therapy to CDMO Scope via $554M Forge Bio Buyout
Ajinomoto’s Forge Biologics acquisition brings contract development and manufacturing organization capabilities in gene therapy. Forge specializes in manufacturing AAV vectors used to deliver these therapies.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Bayer’s New $250M Cell & Gene Therapy Site Signals More Investments to Come
Bayer opens its new cell therapy manufacturing facility as it prepares a Parkinson’s disease cell therapy for Phase 2 testing. The new 100,000 square foot facility also has space for manufacturing other cell therapies in the pharma giant’s pipeline.
-
Cell Therapy Pioneers Team Up to Found Viral Vector CDMO Backed by $64M
VintaBio manufactures AAV and lentiviral vectors for entities pursuing clinical development of cell and gene therapies. The contract development manufacturing organization’s launch comes as demand for viral vectors continues to outpace the supply of these crucial components of the therapies.
-
BIO panel: How Covid-19 is preparing us to better respond to the next pandemic
Biopharmaceutical companies and public health officials have learned a great deal about pandemic response in the last two years. A panel discussion during the annual meeting of the Biotechnology Innovation Organization explored some of the lessons from Covid-19 and how they can prepare us for the next pandemic.
-
Biologics manufacturing drives Evotec’s $435M U.S. stock market debut
Evotec is an old player in the life sciences, but in offering new shares on the Nasdaq, the Germany-based company plans to bolster its new biologics manufacturing capabilities in the U.S and Europe. In other stock market debuts, IO Biotech’s IPO raised $100 million as it prepares a pivotal test of its lead cancer immunotherapy.
-
Catalent sees $1B Bettera deal as a key to growth in nutrition and consumer health
Tie-ups of candy makers and nutritional product companies into a single firm called Bettera has culminated in a $1 billion acquisition by Catalent. The global contract manufacturing giant plans to leverage Bettera’s ability to produce gummies and chewables as a way to offer its customers new formulation options for nutraceutical products.
-
INVEST Precision Medicine Conference Video: Biologics and the Supply Chain Ballet
This panel highlights how different organizations in the biopharma supply chain are addressing the inherent challenges of producing and delivering cell and gene therapies and biologics.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
Cell, gene therapies are highly personalized, but manufacturing needs to be standardized
Cell and gene therapy companies currently each have their own “cookie recipe” for manufacturing. But to scale, more standardization is needed, experts said.
-
Startups, Artificial Intelligence, BioPharma, Health Tech
Funding roundup: Mental health startup led by former Uber exec gets $100 million
Mindstrong, a company offering a mental health platform for patients with serious mental illness, raised $100 million. Read more about startups that raised funding this week.
-
Kite Pharma to expand manufacturing capacity with Maryland plant
The company, part of Gilead Sciences since 2017, had placed an early emphasis on ensuring manufacturing capacity could meet demand – a key consideration in cell and gene therapy.
-
When it comes to cell, gene therapy, manufacturing is ‘Question one, two and three’
Panelists discussed the outlook for cell and gene therapy investing at the Alliance for Regenerative Medicine’s Cell & Gene Therapy Investor Day in New York Thursday.
-
In-house CAR-T manufacturing preferable to outsourcing, execs say
Keeping manufacturing close to home allows for greater flexibility, lower long-term costs and building up native manufacturing capability, panelists said at the B. Riley Health Conference Tuesday.